The Pharmaceutical Journal
Vol 275 No 7380 p752
17 December 2005

This article
Reprint   Photocopy

PDF 40K, Acrobat Reader

· Connecting for health
· Packaging
· Preregistration payments
· Other professions
· The Guild
· Pharmacy monitoring
· Internet eye drops
· Preregistration training
· The Journal

Letters to the Editor

Internet eye drops

A warning from the FDA

From Mr M. M. Furnell, MRPharmS, and others

We wish to bring to pharmacists’ attention an item on the safety of certain eye drops products which are available in UK only from the internet. On 29 November 2005 the US Food and Drug Administration stopped the manufacture and distribution of products made by the American manufacturer Molecular Biologics (MBI Distributing Inc).¹ These products included Bright Eyes and Can-C, among others. These two products are promoted on various websites for rejuvenating tired eyes and claim to reduce cataracts.

Consumers, health care providers, and caregivers are recommended by the FDA to dispose of these products. Pharmacists in the UK should be aware of this statement and advise their patients to stop using these drops if they are known to have purchased them, and to report any adverse reactions to the Medicines and Healthcare Products Regulatory Agency.

Malcolm Furnell
Lead Pharmacist, Ophthalmology
Michael Pettit
Principal Pharmacist
Saul Rajak
Vincent Dubois
Senior House Officers
Sussex Eye Hospital, Brighton

Reference

1. Manufacturer of over-the-counter eye drops signs consent decree with FDA”, FDA News. 29 November 2005.

Send your letter to The Editor

Previous Topic (Pharmacy monitoring)
Next Topic (Preregistration training)